JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

160 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2026, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. Mai 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. Mai 2026, 18:37 UTC

Wichtige Markttreiber

Senseonic Shares Slide on Underwritten Offering Price

1. Mai 2026, 16:46 UTC

Wichtige Markttreiber

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. Mai 2026, 19:57 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. Mai 2026, 15:24 UTC

Ergebnisse

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. Mai 2026, 12:46 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. Mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Mai 2026, 20:42 UTC

Ergebnisse

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. Mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. Mai 2026, 19:18 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. Mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. Mai 2026, 18:36 UTC

Ergebnisse

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. Mai 2026, 18:35 UTC

Ergebnisse

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. Mai 2026, 18:28 UTC

Ergebnisse

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. Mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. Mai 2026, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Barclays Completes Acquisition of Best Egg

1. Mai 2026, 18:04 UTC

Ergebnisse

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. Mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. Mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. Mai 2026, 17:30 UTC

Market Talk

Ergebnisse

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. Mai 2026, 17:28 UTC

Market Talk

Ergebnisse

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. Mai 2026, 17:21 UTC

Market Talk

Ergebnisse

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. Mai 2026, 17:19 UTC

Market Talk

Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. Mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. Mai 2026, 16:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. Mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

160 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.